Lazard Capital Starts AspenBio Pharma (APPY) at Buy
More News related to APPY
- Patient Enrollment for AspenBio Pharma's FDA 510(k) Clinical Trial for AppyScore(TM), World's First Appendicitis Blood Test, Nearing Halfway Point
- AspenBio Pharma to Present at the Noble Financial Equity Conference
- AspenBio Pharma to Present at the 28th Annual Canaccord Adams Global Growth Conference
- Michael R. Merson Joins AspenBio Pharma's Board of Directors
- AspenBio Pharma Joins Russell Microcap Index
More News related to New Coverage
- Renowned PRO Experts, Bio-IT World Editor-in-Chief to Keynote PHT's Educational ePRO Conference
- Ryder Named One of Top 50 Companies for Latinas by LATINA Style Magazine
- Research and Markets: Palm, Inc. - SWOT Analysis Provides All the Crucial Company Information You Require
- Comdisco Announces Distribution to Contingent Distribution Rights Holders and Reallocation of Reserve to Contingent Distribution Rights Holders
- Otterbourg, Steindler, Houston & Rosen Adds Technology Law Expert Richard Raysman
Lazard Capital initiates coverage on AspenBio Pharma Inc. (Nasdaq: APPY) with a Buy rating and $15 price target.
AspenBio Pharma, Inc., a bio-pharmaceutical company, engages in the discovery, research, development, manufacture, and licensing or marketing of drugs and diagnostics for human and animal healthcare.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
